GlassScriptPhysician profile
Dewey Y Mcwhirter
NPI 1215050117
$3,432.68
in general payments reported to CMS, 2019-2025
12 companies · $725 in 2025
The $725 reported for 2025 was more than what a typical Sleep Medicine (Psychiatry & Neurology) provider received nationally (typical 2025 total: $337).
See the full distribution for Sleep Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $224 · 2020: $72.35 · 2021: $170 · 2022: $1,026 · 2023: $609 · 2024: $607 · 2025: $725.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,729 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,728.73 |
| Education | $211.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $1,152.56 | 2019-2025 | |
| Axsome Therapeutics, INC. | $564.50 | 2022-2025 | Sunosi |
| Harmony Biosciences LLC | $450.09 | 2020-2023 | Wakix |
| Inspire Medical Systems, INC. | $446.93 | 2023-2025 | Inspire |
| Philips North America LLC | $295.20 | 2019-2024 | (7999) Src Und |
| Avadel Cns Pharmaceuticals, LLC | $188.92 | 2023-2025 | Lumryz |
| Idorsia Pharmaceuticals US INC | $138.54 | 2022-2024 | Quviviq |
| Fisher & Paykel Healthcare INC | $62.05 | 2022-2024 | Fisher & Paykel Healthcare |
| Resmed Corp | $50.41 | 2021-2023 | |
| Lilly USA, LLC | $49.57 | 2025 | Zepbound |
| 3b Medical, INC. | $21.27 | 2025 | Luna |
| Eisai INC. | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dewey Mcwhirter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.